CSA Medical Announces First Patient Treatment with truFreeze® System, New Rapid AV Spray Catheter

BOSTON, Oct. 2, 2017 /PRNewswire/ -- CSA Medical announced today that the first patient treatment using the new Rapid AV Spray Catheter was completed at the University of Rochester Medical Center by Dr. Vivek Kaul for the management of persistent symptomatic esophageal cancer and associated dysplastic Barrett's disease.  Recently cleared for use with the truFreeze System, the Rapid AV catheter represents a major advance over prior technology. The prior polymer with embedded metal braid material is replaced by a stainless steel catheter wall resulting in a 50% reduction in time to liquid nitrogen spray delivery to the treatment site, thus decreasing overall treatment time as well.

The truFreeze System is indicated for use as a cryosurgical tool in the fields of dermatology, gynecology, and general surgery, to ablate benign (e.g. Barrett's Esophagus with high grade dysplasia and/or low grade dysplasia) and malignant lesions. 

Dr. Vivek Kaul, the Segal-Watson Professor of Medicine and Chief, Division of Gastroenterology & Hepatology at the University of Rochester notes "with a significantly reduced time to 'spray actuation' and a uniform, non-dissipating freeze pattern, we found the Rapid AV catheter to work reliably, consistently and effectively in a diverse array of clinical settings, from flat Barrett's ablation to bulky tumor palliation."  Together with the new 16F cryogen decompression tube, this catheter will further enhance our ability to more effectively care for our patients with dysplastic Barrett's and esophageal carcinoma.

"This product expansion solidifies truFreeze liquid nitrogen spray cryotherapy as the only ablation solution for the full range of Barrett's Esophagus disease as well as esophageal cancer," says Ellen Sheets MD, CEO and President of CSA Medical.

About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreeze^® system which is currently used to ablate benign (e.g. Barrett's Esophagus with high grade dysplasia) and malignant lesions.

To learn more about our technology, please visit http://csamedical.com/.

truFreeze is a registered trademark of CSA Medical, Inc.

For further information contact:
Amy Sarli, CSA Medical
+1-781-538-4779 / [email protected]

SOURCE CSA Medical, Inc.

Related Links

http://www.csamedical.com